Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.50 |
| ▸ | KLK7 | P49862 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | CASR | P41180 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6726997 | 0.88 | MAPT (0.50) | LMNACASRNPC1RAB9AKMT2A | |
| SCHEMBL6714045 | 0.88 | MAPT (0.61) | LMNANPC1RAB9AKMT2AMEN1 | |
| SCHEMBL6718048 | 0.86 | KLK7 (0.46) | KLK7LMNANPC1RAB9AKMT2A | |
| SCHEMBL6713823 | 0.84 | IMPDH2 (0.47) | LMNANPC1RAB9AKMT2AMEN1 | |
| SCHEMBL6719260 | 0.84 | MAPT (0.51) | LMNANPC1RAB9AKMT2AMEN1 | |
| SCHEMBL6715668 | 0.81 | RAB9A (0.53) | LMNANPC1RAB9AKMT2AMEN1 | |
| SCHEMBL6722745 | 0.79 | MAPT (0.53) | LMNARAB9AKMT2AMEN1GAA | |
| SCHEMBL6715571 | 0.79 | KDM4E (0.50) | LMNANPC1RAB9AKMT2AMEN1 | |
| SCHEMBL6719552 | 0.79 | CYP1A2 (0.52) | KLK7LMNANPC1RAB9AKMT2A | |
| SCHEMBL6715747 | 0.78 | MAPT (0.52) | LMNANPC1RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152741-A1 | Arylglycine derivatives and their use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152741-A1 | Arylglycine derivatives and their use as glycine transport inhibitors | SLC1A2, SLC1A1, SLC7A11 | NPY5R 1179/4885KLK7 3279/4885LMNA 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.